warm autoimmune hemolytic anamie, wAIHA, AIHA, Immune-mediated red blood cell destruction
Conditions
Interventions
None listed
Sponsors
Universitair Medisch Centrum Groningen
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: General:Able to understand the Dutch study information for patients/volonteers.Signed informed consentAge= 18 years Cases: Patients with active warm AIHA: primary or secondary to SLE/CLL:Active hemolysis due to warm AIHA* *Active AIHA: a positive direct antiglobulin test (positive for IgG and/or IgA) and decreased haptoglobin in combination with: Anemia + increased LDH and/or increased unconjugated bilirubin.Or Reticulocytosis + increased LDH and/or increased unconjugated bilirubin. Controls: Healthy volunteers and patients with SLE/CLL but without ever hemolysis and without a positive direct antiglobulin test. Healthy# or diagnosed with CLL or SLE #Definition of healthy:Patients without anaemia, current infection, use of systemic immunosuppressants, history of malignancy (non-melanoma skin cancer excluded) and/or systemic disease.
Exclusion criteria
Exclusion criteria: All participants:Red blood cell transfusion in the last 6 months before inclusionActive infection Cases: Secondary AIHA due to another cause than SLE or CLL
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Differences in erythrocyte properties between cases and controls The relation between erythrocyte properties and the severity of hemolysis, time to treatment response and the risk of relapse within the cohort of AIHA patients | — |
Secondary
| Measure | Time frame |
|---|---|
| Differences in immune response | — |
Countries
Netherlands
Contacts
Public ContactH.A.M. Kooistra
Universitair Medisch Centrum Groningen
Outcome results
None listed